Abstract
Surgery and chemotherapy are the two main measures to treat epithelial ovarian cancer(EOC), and satisfied cytoreductive surgery is the key precondition of successful chemotherapy. Although new drugs or regimens emerge constantly, incidence of recurrence of epithelial ovarian cancer reaches up to 80%, however, chemotherapy resistance is the basic reason of the recurrence. Even though, some of these drugs or regimens bring about some promise to patients with epithelial ovarian cancer. Gemcitabine has been approved to apply to chemotherapy of patients with recurrent epithelial ovarian cancer whose platinum-free interval is more than 6 months by Food and Drug Administration (FDA) in the year of 2006. We reviewed its current application and development in epithelial ovarian cancer in recent years as followed. Key words: epithelial ovarian cancer(EOC); chemotherapy; gemcitabine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
